About CellProthera
CellProthera is a company based in Mulhouse (France) founded in 2008 by Jean-Claude Jelsch and Philippe Henon. CellProthera has raised $31.29 million across 10 funding rounds from investors including Bpifrance, European Union and EIC Fund. CellProthera offers products and services including ProtheraCytes. CellProthera operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others.
- Headquarter Mulhouse, France
- Founders Jean-Claude Jelsch, Philippe Henon
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cellprothera
-
Annual Revenue
$11.38 K (USD)36as on Dec 31, 2016
-
Net Profit
-$3.66 M (USD)-201as on Dec 31, 2016
-
EBITDA
$4.57 M (USD)24as on Dec 31, 2016
-
Total Equity Funding
$31.29 M (USD)
in 10 rounds
-
Latest Funding Round
$6.06 M (USD), Grant
Apr 30, 2021
-
Investors
Bpifrance
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CellProthera
CellProthera offers a comprehensive portfolio of products and services, including ProtheraCytes.
Expanded CD34+ cells for revascularizing ischemic lesions
Funding Insights of CellProthera
CellProthera has successfully raised a total of $31.29M across 10 strategic funding rounds. The most recent funding activity was a Grant round of $6.06 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CellProthera
CellProthera has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Bpifrance, European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
SODIV is engaged in supporting SMEs in Grand Est.
|
Locked | Locked | Locked | |
|
Local economic development is supported through investments in Alsace.
|
Locked | Locked | Locked |
Investor details for CellProthera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CellProthera
Investment portfolio details for CellProthera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CellProthera
Detailed financials for CellProthera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellprothera Comparisons
Peer comparison for CellProthera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CellProthera
CellProthera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, Arrakis Therapeutics, MyoKardia and Eiger BioPharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Specialized drugs are developed for genetic heart diseases.
|
|
| Locked | Locked | Locked |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| Locked | Locked | Locked |
Cell therapy for diabetes is developed from stem cells.
|
Detailed competitors of CellProthera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellprothera
Complete news archive for CellProthera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CellProthera
CellProthera was founded in 2008 and raised its 1st funding round 1 year after it was founded.
CellProthera is headquartered in Mulhouse, France. It is registered at Mulhouse, Grand Est, France.
Matthieu de Kalbermatten is the current CEO of CellProthera.
CellProthera is a funded company, having raised a total of $31.29M across 10 funding rounds to date.
Annual revenue of CellProthera is $11.38K as on Dec 31, 2016.
CellProthera was established in 2008 in Mulhouse, France, within the regenerative medicine sector. Focus is placed on cardiac repair through a bioproduction platform that expands CD34 cells, termed ProtheraCytes. These cells are used to support angiogenesis and revascularization in ischemic areas. The therapy entails injection of CD34 cells into individuals with severe myocardial infarction, aiming to enhance cardiac function over time. Operations center on advancing these treatments for clinical application.
CellProthera's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
CellProthera offers ProtheraCytes.
CellProthera has 5 investors. Key investors include Bpifrance, European Union, EIC Fund, SODIV, and Alsace Business Angels.